Author: super@dmin
-

NerdWallet: How does inflation affect stocks? Here’s an explainer, and a basic guide to finding the stocks that fare better with inflation.
Inflation affects some stocks less than others, and it can even be good for certain sectors of the market.
-

Next Avenue: Celebrating your retirement? Don’t delete your LinkedIn profile yet.
Whether you plan a working or leisure-based retirement, LinkedIn can help you stay connected to interesting people and ideas.
-

: Stock in Orpea slumps 34% as French care home operator resumes trading
Shares in French care home group Orpea has fallen 34% on Wednesday as it resumed trading on the Paris Stock Exchange after regulators suspended trading on Monday.
-

: New York has the most expensive rents in the U.S. This city is No. 2…
Despite rent spikes in a handful of cities, rent growth continues to cool nationwide.
-

: U.K. government may miss date for announcing new fiscal plan.
Markets shrug off the news, happy that new Sunak/Hunt team is at the controls
-

Dow Jones Newswires: Barclays profit and income beat forecasts
Barclays said its diversified income streams position it well for the current economic and market environment, including rising interest rates.
-

Dow Jones Newswires: Norwegian Air Shuttle net profit boosted by pent-up summer demand
Current booking trends are encouraging, although visibility is low, with many customers booking travels close to date of departure, the airline said.
-

Dow Jones Newswires: Iberdrola backs profit guidance after 9 month earnings rise
The Spanish energy company said net profit rose to 3.10 billion euros ($3.07 billion) in the period driven by a strong performance in the U.S. and Brazil.
-

Dow Jones Newswires: Heineken backs full-year guidance after posting 20% revenue rise
Total organic beer volumes rose 8.9% in the quarter. For the first nine months of the year, beer volumes rose 8.1%.
-

Dow Jones Newswires: AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints
The Anglo-Swedish pharma giant said the trial met both primary endpoints of improving progression-free survival in the overall patient population and in a prespecified biomarker subgroup of patients whose tumors had qualifying alterations.